Press releases
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
- Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
- Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 157.66 |
---|---|
High | 157.66 |
Low | 157.66 |
Bid | 154.11 |
Offer | 155.25 |
Previous close | 98.31 |
Average volume | -- |
---|---|
Shares outstanding | 17.71m |
Free float | 16.66m |
P/E (TTM) | 24.95 |
Market cap | 1.28bn USD |
EPS (TTM) | 2.91 USD |
Data delayed at least 15 minutes, as of Mar 15 2021.
More ▼